Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Initial Monthly Cost of Tafamidis—the Real Price for Patients

Initial Monthly Cost of Tafamidis—the Real Price for Patients Letters Shirley Stasher, RN COMMENT & RESPONSE Daniel W. Jones, MD Initial Monthly Cost of Tafamidis— Richard Summers, MD the Real Price for Patients To the Editor We concur entirely with the Viewpoint by Author Affiliations: Division of Cardiology, Department of Medicine, University of Mississippi Medical Center, Jackson (Clark); Center for Telehealth, Gurwitz and Maurer on the high price of tafamidis for the University of Mississippi Medical Center, Jackson (Woods, Stasher, Summers); treatment of transthyretin amyloidosis cardiomyopathy Mississippi Center for Clinical and Translational Research, University of Missis- (ATTR-CM). The authors briefly addressed the potential sippi Medical Center, Jackson (Patki, K. Jones); Department of Medicine, Uni- problem of access and affordability for patients but do not versity of Mississippi Medical Center, Jackson (D. W. Jones); Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson provide details on cost. As this is a disease of the elderly, (D. W. Jones). most patients in the US receiving tafamidis are Medicare Accepted for Publication: March 10, 2020. beneficiaries. Medicare has a multilayered structure for Corresponding Author: Donald Clark III, MD, MPH, Division of Cardiology, drug coverage, and patients may be subject to high copay- Department of Medicine, University of Mississippi Medical http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Cardiology American Medical Association

Initial Monthly Cost of Tafamidis—the Real Price for Patients

Loading next page...
 
/lp/american-medical-association/initial-monthly-cost-of-tafamidis-the-real-price-for-patients-yp5lrMFmuT
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2380-6583
eISSN
2380-6591
DOI
10.1001/jamacardio.2020.0863
Publisher site
See Article on Publisher Site

Abstract

Letters Shirley Stasher, RN COMMENT & RESPONSE Daniel W. Jones, MD Initial Monthly Cost of Tafamidis— Richard Summers, MD the Real Price for Patients To the Editor We concur entirely with the Viewpoint by Author Affiliations: Division of Cardiology, Department of Medicine, University of Mississippi Medical Center, Jackson (Clark); Center for Telehealth, Gurwitz and Maurer on the high price of tafamidis for the University of Mississippi Medical Center, Jackson (Woods, Stasher, Summers); treatment of transthyretin amyloidosis cardiomyopathy Mississippi Center for Clinical and Translational Research, University of Missis- (ATTR-CM). The authors briefly addressed the potential sippi Medical Center, Jackson (Patki, K. Jones); Department of Medicine, Uni- problem of access and affordability for patients but do not versity of Mississippi Medical Center, Jackson (D. W. Jones); Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson provide details on cost. As this is a disease of the elderly, (D. W. Jones). most patients in the US receiving tafamidis are Medicare Accepted for Publication: March 10, 2020. beneficiaries. Medicare has a multilayered structure for Corresponding Author: Donald Clark III, MD, MPH, Division of Cardiology, drug coverage, and patients may be subject to high copay- Department of Medicine, University of Mississippi Medical

Journal

JAMA CardiologyAmerican Medical Association

Published: Jul 22, 2020

References